|Articles|April 13, 2022
Improving Titer, Quality and Efficiency of AAV Manufacturing and Production by Optimizing Osmolality
Author(s)Advanced Instruments
Modulating osmolality in the early stages of AAV1 upstream manufacturing, can result in improved outcomes such as overall yield, quality, reduced manufacturing costs and improved efficiencies.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Formulation Strategies, Tech Advances, Challenges, and Considerations in Novel Drug Delivery
2
FAQ: What You Need to Know About How Industry is Tackling CGT Bottlenecks
3
Drug Digest: Biopharma Landscape Evolves Through Strategic Alliances and Technology Integration
4
BioPharm Weekly News Roundup—Week of Nov. 24, 2025
5
